<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988452</url>
  </required_header>
  <id_info>
    <org_study_id>JC3218</org_study_id>
    <nct_id>NCT03988452</nct_id>
  </id_info>
  <brief_title>Nucleosides And Darunavir/Dolutegravir In Africa</brief_title>
  <acronym>NADIA</acronym>
  <official_title>Nucleosides And Darunavir/Dolutegravir In Africa (NADIA): a Randomised Controlled Trial of Darunavir Versus Dolutegravir and Tenofovir Versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Diseases Institute, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates options for second-line antiretroviral therapy in patients failing on a&#xD;
      non-nucleoside reverse transcriptase inhibitor (NNRTI) and tenofovir (TDF)-based first-line&#xD;
      regimen in the setting of the public health approach in sub-Saharan Africa (with assumed&#xD;
      substantial nucleoside reverse transcriptase inhibitor (NRTI) cross-resistance). The trial&#xD;
      tests two hypotheses. Firstly that a regimen of dolutegravir (DTG) with two NRTIs is&#xD;
      non-inferior to a regimen of ritonavir-boosted darunavir (DRV/r) with two NRTIs. Secondly&#xD;
      that continuing an NRTI regimen of TDF and lamivudine (3TC) is non-inferior to switching to&#xD;
      zidovudine (ZDV) and 3TC.&#xD;
&#xD;
      The trial is a parallel group, open-label, multi-centre, factorial (2X2) randomised,&#xD;
      controlled trial. Patients will be randomised to either DTG or DRV/r with a second&#xD;
      randomisation to ZDV and 3TC or TDF and 3TC. Treatment efficacy will be monitored by testing&#xD;
      viral load (VL). Analyses will compare DRV/r with DTG; and ZDV/3TC with TDF/3TC by intention&#xD;
      to treat analysis on the primary outcome parameter of plasma VL below 400 copies/ml at 48&#xD;
      weeks. Trial follow-up will continue to 96 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma viral load &lt; 400 copies/ml at 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load &lt; 1000 copies/ml</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load &lt; 400 copies/ml at 96 weeks</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load &lt; 50 copies/ml</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load rebound (≥ 1000 copies/ml, confirmed)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load rebound (≥ 400 copies/ml, confirmed)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load rebound (≥ 50 copies/ml, confirmed)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load rebound (≥ 1000 copies/ml, confirmed) with ≥ 1 major resistance mutation (IAS list) to DRV or DTG</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load rebound (≥ 1000 copies/ml, confirmed) with intermediate or high-level resistance (Stanford algorithm) to DRV or DTG</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load rebound (≥ 1000 copies/ml, confirmed) with intermediate or high-level resistance (Stanford algorithm) to both zidovudine and tenofovir</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ cell count change from baseline</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident (new or recurrent) WHO stage 4 event</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident serious non-AIDS event</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to new or recurrent WHO Stage 4 event, serious non-AIDS event, or death</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 clinical adverse events</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 clinical adverse events (possibly, probably or definitely related to ART)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">465</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darunavir 800mg once daily Ritonavir 100mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darunavir 800mg once daily Ritonavir 100mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir Zidovudine Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir Tenofovir Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Dolutegravir Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Tenofovir Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age 12 years and above&#xD;
&#xD;
          2. Body weight at least 40kg&#xD;
&#xD;
          3. Taking a tenofovir plus lamivudine/emtricitabine plus NNRTI-based regimen continuously&#xD;
             for a total period of at least 6 months&#xD;
&#xD;
          4. Good adherence to ART, defined as missing medication on no more than 3 days in the one&#xD;
             month prior to screening. [Patients who do not have good adherence should be given&#xD;
             adherence counselling and re-assessed after an interval of not less than 4 weeks].&#xD;
&#xD;
          5. HIV treatment failure defined by virological criteria (modified from WHO 2016&#xD;
             criteria); Viral load ≥ 1000 copies/ml at screening AND EITHER Viral load ≥ 1000&#xD;
             copies/ml on the previous test, taken after at least 6 months on ART, and at no more&#xD;
             than 6 months prior to screening and at no less than 4 weeks prior to screening, with&#xD;
             adherence counselling given after the previous test OR Viral load ≥ 1000 copies/ml on&#xD;
             a confirmatory test taken no less than 4 weeks after screening with adherence&#xD;
             counselling given after the screening test&#xD;
&#xD;
          6. If a woman of childbearing potential, must be willing to use effective contraception.&#xD;
             [Childbearing potential is defined as being not premenarchal; not post-menopausal (&gt;&#xD;
             12 months of spontaneous amenorrhea and ≥45 years of age); and not permanently&#xD;
             sterilised].&#xD;
&#xD;
          7. Willing and able to provide written informed consent&#xD;
&#xD;
          8. Able to attend regular study follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior use of protease inhibitor or integrase inhibitor therapy&#xD;
&#xD;
          2. Requirement for concomitant medication with known major interactions with study drugs&#xD;
             for which drug substitutions or dose alterations are not available or acceptable (if&#xD;
             the patient requires rifamycin-based TB treatment, rifabutin must be available at the&#xD;
             site).&#xD;
&#xD;
          3. Women who are currently pregnant or breastfeeding.&#xD;
&#xD;
          4. Severe hepatic impairment (with ascites and/or encephalopathy)&#xD;
&#xD;
          5. ALT &gt; 5 times upper limit of normal&#xD;
&#xD;
          6. Estimated glomerular filtration rate (eGFR) &lt; 50 ml/min/1.73m2 at screening calculated&#xD;
             using the CKD-EPI equation&#xD;
&#xD;
          7. Current participation in another clinical trial or research protocol (may be permitted&#xD;
             in some circumstances; but must first be discussed with the NADIA Chief Investigator)&#xD;
&#xD;
          8. Life expectancy of less than one month in the opinion of the treating physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Paton, MD</last_name>
    <role>Study Director</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

